Cochrane · systematic review · CD007470
Vitamin D supplementation for prevention of mortality in adults
Bjelakovic, G, Gluud, LL, Nikolova, D, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 28.6%Very low 0 · 0%Low 2 · 28.6%Moderate 3 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyVitamin D supplementation for prevention of mortality in adults
Population: adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality in trials using vitamin D3 (cholecalciferol) ( | RR 0.94 [0.91, 0.98] | 38 studies · 75927 participants | Moderate Downgraded: risk of bias |
Cardiovascular mortality in trials using vitamin D3 (cholecalciferol) ( | RR 0.98 [0.9, 1.07] | 10 studies · 47267 participants | Low Downgraded: risk of bias, imprecision |
Cancer mortality in trials using vitamin D3 (cholecalciferol) ( | RR 0.88 [0.78, 0.98] | 4 studies · 44492 participants | Moderate Downgraded: risk of bias |
Adverse events: nephrolithiasis in trials using vitamin D3 combined with calcium ( | RR 1.17 [1.02, 1.34] | 4 studies · 42876 participants | Moderate Downgraded: risk of bias |
Adverse events: hypercalcaemia in trials using the active forms of vitamin D (alfacalcidol and calcitriol) ( | RR 3.18 [1.17, 8.68] | 3 studies · 710 participants | Low Downgraded: risk of bias, imprecision |
Health‐related quality of life ( | no estimate extracted | 1 study · 105 participants | Ungraded |
Health economics ( | no estimate extracted | 1 study · 3270 participants | Ungraded |
Vitamin D supplementation for prevention of mortality in adults
Population: adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality in trials using vitamin D3 (cholecalciferol) | RR 0.94 [0.91, 0.98] | 32 studies · 74789 participants | High |
Cardiovascular mortality | RR 1.01 [0.91, 1.13] | 10 studies · 42589 participants | High |
Cancer mortality | RR 0.89 [0.78, 1.02] | 3 studies · 39200 participants | High |
Adverse events ‐ Nephrolithiasis in trials using vitamin D3 combined with calcium | RR 1.17 [1.02, 1.34] | 4 studies · 42876 participants | High |
Adverse events ‐ Hypercalciuria | RR 4.64 [0.99, 21.76] | 3 studies · 695 participants | Low |
Health‐related quality of life | no estimate extracted | NR | No studies |
Health economics | no estimate extracted | NR | No studies |